The science and technology infrastructure in drug discovery for central nervous system (CNS) diseases and disorders has been greatly developed over the past decade. Various hypotheses have been proposed about the pathogenesis and progression of CNS diseases and disorders, and efforts to develop new drugs for rare diseases are also becoming active. The drug modalities have expanded from small molecules to medium molecules, antibodies, proteins, nucleic acids, cells, and even digital, and the drug discovery process is changing dramatically. Drug discovery researchers require a wide variety of specialized knowledge and techniques. As research tools such as human induced pluripotent stem cells and genetically modified animals become increasingly complex, it is often difficult to prepare and procure them within a pharmaceutical corporation. Furthermore, patient stratification in clinical studies and translational research to predict the efficacy of drug candidates have become important pillars in drug discovery research. Under such circumstances, it is becoming difficult for pharmaceutical corporations to complete all elements necessary for drug discovery research on their own, and collaboration with partners with expertise is becoming essential to improve the quality and speed of research. In this presentation, I would like to introduce what corporations are seeking, hoping that this symposium will generate some ideas for new approaches and collaborations.